Impact of Platelet Reactivity on 1-Year Clinical Outcomes After Endovascular Therapy for Femoropopliteal Lesions

Dual antiplatelet therapy with aspirin plus P2Y12 inhibitor for at least 1  month after endovascular therapy (EVT) is recommended in symptomatic lower extremity arterial disease (LEAD) with femoropopliteal (FP) lesions.1 However, the pharmacodynamic response to antiplatelet medication differs between individuals. In particular, greater individual differences in platelet r eactivity to clopidogrel, one of the P2Y12 inhibitors, have been reported compared with aspirin.2 Several previous studies evaluated the association of platelet reactivity with clinical outcomes in the area of LEAD management, but their conclusions were inconsistent.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Tags: Brief Report Source Type: research